Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.

ABSTRACT:

Purpose

Evaluate real-world outcomes in three cohorts of patients with early-stage triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC): (1) patients who achieved pathological complete response (pCR); (2) patients without pCR who didn't receive adjuvant chemotherapy; and (3) patients without pCR who received adjuvant capecitabine.

Methods

Retrospective cross-sectional study from two hospitals in Málaga. Patients with TNBC received standard NAC followed by surgery. Between 2004 and 2015, patients not achieving pCR received no further systemic therapy. From 2015 onward, these patients were treated with adjuvant capecitabine. Kaplan-Meier and log-rank tests were used to compare disease-free survival (DFS) and overall survival (OS).

Results

A t

SUBMITTER: Godoy-Ortiz A 

PROVIDER: S-EPMC12665565 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature